Pioglitazone in Alzheimer Disease

Alzheimer Disease Clinical Trial

Official title:

Pioglitazone in Alzheimer Disease Progression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00982202
• Other study ID #: IA0168
• Secondary ID: 1R01AG018905
• Status: Completed
• Phase: Phase 2
• First received: September 22, 2009
• Last updated: September 22, 2009
• Start date: January 2002
• Est. completion date: January 2005

Study information

• Verified date: September 2009
• Source: National Institute on Aging (NIA)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.

Description:

Inflammatory processes are important in the progressive loss of memory and thinking skills in Alzheimer's disease (AD). Laboratory studies show that drugs that bind to a protein known as "Peroxisome Proliferator Activated Receptor-gamma (PPARgamma)" act to reduce inflammatory responses in brain cells known as microglia when they are exposed to amyloid peptide, a major part of AD pathology. Therefore, drugs that activate PPARgamma have great potential for reducing the progression of AD. Pioglitazone (PGZ) activates PPARgamma and has shown favorable clinical experiences and safety profiles in patients with diabetes. This is a pilot study to determine the safety and tolerability of PGZ in patients with AD. Another goal of the study is to assess how clinical measures of cognition, daily function, and behavior might respond to PGZ treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: January 2005
• Est. primary completion date: January 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• CT or MRI since disease onset excluding structural lesions sufficient to account for the participant's dementia

• Mini-Mental State Exam (MMSE) score between 12 and 26, inclusively

• Clinical Dementia Rating (CDR) score of 1 or 2 (mild to moderate AD severity) at both screening and baseline

• Women must be 2-years post-menopausal or surgically sterile.

• Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane); vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures

• Concomitant medications: Participants may be on stable doses of cholinesterase inhibitors for 90 days prior to screening (may not be started during the trial); antidepressant or antipsychotic medications are acceptable if symptoms are controlled and therapy is at stable dosage for at least 30 days prior to screening; vitamin E at 200 IU daily will be provided to all participants beginning at baseline/randomization (higher doses must be discontinued at the screening visit)

Exclusion Criteria:

• Absence of a reliable caregiver who is willing to participate and comply with protocol responsibilities

• Diabetes mellitus requiring medical therapy (diet-controlled diabetes is acceptable)

• Acute or chronic liver failure, hepatitis within the last two years, or history of drug-induced liver transaminase elevations

• Heart failure meeting New York Heart Association Grade III or IV criteria (i.e., functionally disabling)

• Evidence of active gastrointestinal, renal, pulmonary, endocrine or cardiovascular system disease sufficient to cause cognitive impairment or interfere with past levels of daily function; participants with controlled hypertension (supine diastolic BP < 95mmHg), right bundle branch block (complete or partial) and pacemakers may be included in the study; participants with thyroid disease also may be included in the study, provided they are euthyroid on treatment

• Active treatment for cancer or history of cancer within 3 years of screening (basal cell and squamous cells skin cancers are acceptable; incidental finding of carcinoma cells at transurethral prostate resection without subsequent medical or surgical therapy is acceptable)

• Evidence of other psychiatric/neurologic disorders sufficient to be the primary source of cognitive impairment (i.e., stroke, idiopathic Parkinson's disease, schizophrenia, bipolar or unipolar depression, seizure disorder, head injury with loss of consciousness within the past year) or a modified Hachinski's ischemia score of 5 or greater; delusions, hallucinations or depression not successfully treated or not on stable medical therapy for these conditions 30 days prior to enrollment; known or suspected history (within the past 10 years) of alcoholism or drug misuse

• Participants and/or caregivers who are unwilling or unable to fulfill the requirements of the study

• Any condition which would make the participant or the caregiver, in the opinion of the investigator, unsuitable for the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• pioglitazone
15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for ~18months
• Placebo
1 to 3 tablets daily for ~18 months

Locations

Country	Name	City	State
United States	University of Virginia	Charlottesville	Virginia
United States	University Hospitals of Cleveland	Cleveland	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
National Institute on Aging (NIA)	Takeda Pharmaceuticals North America, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005 Jun;128(Pt 6):1442-53. Epub 2005 Apr 7. — View Citation

Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs. 2008;22(1):1-14. Review. — View Citation

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007 Sep 12;298(10):1180-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of adverse events		baseline, monthly for 1 year, then 15 and 18 months	Yes
Secondary	Laboratory abnormalities		baseline, monthly for 1 year, then 15 and 18 months	Yes
Secondary	Cognition		baseline, 3, 6, 9, 12, 15, and 18 months	No
Secondary	Activities of Daily Living (ADL)		baseline, 3, 6, 9, 12, 15, and 18 months	No
Secondary	Behavior		baseline, 3, 6, 9, 12, 15, and 18 months	No
Secondary	Global function		baseline, 3, 6, 9, 12, 15, and 18 months	No